Phase 2. Xxxxx 0, Xxxxxx to Non-Market, consists of the continuation of all Phase 1 elements (except those that have been completed or due to other circumstances cannot be continued) and, in addition, may consist of the following elements:
Phase 2. The second phase of the Training ("Phase 2") shall be ------- provided for up to three (3) Trainees who have mastered the skills taught in Phase 1, will last for up to two (2) weeks, and may be conducted with trainees from other countries. Phase 2 will commence within ninety (90) calendar days after the end of Phase 1. Phase 2 shall cover the following topics:
Phase 2. Phase 2 is expected to consist of Member Nodes and a select number of Nodes operated by non-Members. The non-Member Nodes will be required to comply with Node hosting terms as set forth by the Council, which may be amended from time to time (the “General Node Terms”).
Phase 2. The SSA Onsite Certification is a formal security review conducted by SSA, or on its behalf, to examine the full suite of management, operational, and technical security controls implemented by the EIEP to safeguard data obtained from SSA electronically (refer to The Certification Process). (THE REST OF THIS PAGE HAS BEEN LEFT BLANK INTENTIONALLY)
Phase 2. The Global Fund may decide, in its sole discretion, to extend the Program Term beyond the Phase 1 Ending Date (a “Phase 2 Approval”). If the Global Fund issues a Phase 2 Approval, the parties shall execute an amendment to this Agreement and the “Program Term” shall automatically be extended to the Phase 2 Ending Date (indicated in block 7 the face sheet of this Agreement) or any other date specified by the Global Fund in its Phase 2 Approval.
Phase 2. 2.1 Description & Scope In this phase, POSCO Power/POSCO Affiliate and FCE will jointly develop the next-generation BOP for one of the DFC products, either sub-MW or MW-class, as determined jointly by FCE and POSCO Power/POSCO Affiliate. Technology, information, and know-how related to the BOP for DFC products which are actively being developed under this phase, as well as those which are not actively being developed will be made available as set forth below. Considering resource constraints of both parties and market demands, FCE and POSCO Power/POSCO Affiliate shall determine the scope of their co-development efforts by mutual agreement. This phase work will be aimed at the co-development of a new BOP design which is intended to meet or exceed the FCE cost, performance and quality targets for the next generation of DFC products.
Phase 2. Promptly after the occurrence of the target date identified in the Project Plan for commercial viability of either or both of:
Phase 2. During Phase 2, MBI shall manufacture OPTISON for Mallinckrodt for countries designated by the Joint Steering Committee and subject to the Product Specifications contained in APPENDIX 5, and shall ship it to Mallinckrodt in flex bags. Mallinckrodt shall perform Fill Operations.
Phase 2. Phase 2 includes the controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects.
Phase 2. If determined by the JSC, Anadys will screen the Target against all of the Amgen Library Compounds ([...***...]) anD the Anadys Library Compounds as designated in the Research Plan for activity in the Screening Assay to identify Primary Hits. Anadys will screen the Target against Primary Hits selected by the JSC and perform such other work as set forth in the Research Plan to identify Qualified Hits. In accordance with the Validation Criteria, the JSC shall identify Validated Hits. Anadys will provide Amgen with monthly written updates as to the progress of the screening and will identify all Validated Hits not previously identified to Amgen, and their relevant Screening Assay results. At the end of the screening using a Screening Assay, Anadys will provide Amgen with a written report including comprehensive results of the screening.